文献速递系统性红斑狼疮其他结缔组织病

羟氯喹与SLE患者多自身免疫风险降低相关:RELESSER登记研究

Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

基于西班牙风湿病学会狼疮登记(RELESSER)的3679例SLE患者横断面研究显示,13.6%存在多自身免疫。多因素分析中抗疟药与多自身免疫风险降低相关(OR 0.50,95%CI 0.38–0.67),作者认为该保护性发现需未来研究验证。

要点

  • SLE患者中多自身免疫占13.6%,以自身免疫性甲状腺炎(7.9%)最常见。
  • 抗疟药与多自身免疫风险降低相关(OR 0.50,95%CI 0.38–0.67)。
  • 女性、RP、ILD、Jaccoud关节病及抗Ro/SSA等抗体与多自身免疫相关。

核心结论

  • SLE患者常合并多自身免疫,抗疟药与多自身免疫风险降低相关,但该发现需未来研究验证。

研究设计与样本

  • RELESSER为西班牙风湿病学会全国多中心医院来源SLE登记,本研究为横断面研究,共纳入3679例符合SLE标准的患者。

主要发现

  • 502例(13.6%)存在多自身免疫;最常见类型为自身免疫性甲状腺炎(7.9%),其他系统性自身免疫病占6.2%。
  • 继发性SS占14.1%,继发性APS占13.7%;多重自身免疫综合征占全部多自身免疫的10.2%,家族史记录于11.8%。
  • 多因素分析中与多自身免疫相关的因素包括女性、RP、ILD、Jaccoud关节病、抗Ro/SSA和/或抗La/SSB抗体、抗RNP抗体、MTX及抗疟药。

关键数值与推荐

  • 女性OR 1.72(95%CI 1.07–2.72);RP OR 1.63(95%CI 1.29–2.05)。
  • ILD OR 3.35(95%CI 1.84–6.01);Jaccoud关节病OR 1.92(95%CI 1.40–2.63)。
  • 抗Ro/SSA和/或抗La/SSB抗体OR 2.03(95%CI 1.55–2.67);抗RNP抗体OR 1.48(95%CI 1.16–1.90)。
  • MTX OR 1.67(95%CI 1.26–2.18);抗疟药OR 0.50(95%CI 0.38–0.67)。

临床怎么用

  • 对SLE患者应关注合并其他自身免疫病,尤其是甲状腺炎、继发性SS与APS。
  • 合并RP、ILD、Jaccoud关节病或抗Ro/SSA、抗RNP抗体者多自身免疫风险更高,可加强筛查。
  • 抗疟药与多自身免疫风险降低的关联仅为观察性结果,不能据此改变用药决策,需进一步研究验证。

局限性

  • 为横断面研究,无法确立因果与时间顺序,抗疟药保护作用需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This article estimates the frequency of polyautoimmunity and associated factors in a large retrospective cohort of patients with SLE. METHODS: RELESSER (Spanish Society of Rheumatology Lupus Registry) is a nationwide multicentre, hospital-based registry of SLE patients. This is a cross-sectional study. The main variable was polyautoimmunity, which was defined as the co-occurrence of SLE and another autoimmune disease, such as autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy and MCTD. We also recorded the presence of multiple autoimmune syndrome, secondary SS, secondary APS and a family history of autoimmune disease. Multiple logistic regression analysis was performed to investigate possible risk factors for polyautoimmunity. RESULTS: Of the 3679 patients who fulfilled the criteria for SLE, 502 (13.6%) had polyautoimmunity. The most frequent types were autoimmune thyroiditis (7.9%), other systemic autoimmune diseases (6.2%), secondary SS (14.1%) and secondary APS (13.7%). Multiple autoimmune syndrome accounted for 10.2% of all cases of polyautoimmunity. A family history was recorded in 11.8%. According to the multivariate analysis, the factors associated with polyautoimmunity were female sex [odds ratio (95% CI), 1.72 (1.07, 2.72)], RP [1.63 (1.29, 2.05)], interstitial lung disease [3.35 (1.84, 6.01)], Jaccoud arthropathy [1.92 (1.40, 2.63)], anti-Ro/SSA and/or anti-La/SSB autoantibodies [2.03 (1.55, 2.67)], anti-RNP antibodies [1.48 (1.16, 1.90)], MTX [1.67 (1.26, 2.18)] and antimalarial drugs [0.50 (0.38, 0.67)]. CONCLUSION: Patients with SLE frequently present polyautoimmunity. We observed clinical and analytical characteristics associated with polyautoimmunity. Our finding that antimalarial drugs protected against polyautoimmunity should be verified in future studies.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mena-Vázquez N, Fernández-Nebro A, Pego-Reigosa JM, et al. Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology (Oxford). 2020. PMID: 31808534. doi:10.1093/rheumatology/kez562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。